Advertisment

The EU's BEHIND-MS Consortium: A Beacon of Hope in Multiple Sclerosis Research

author-image
Ethan Sulliva
New Update
NULL

The EU's BEHIND-MS Consortium: A Beacon of Hope in Multiple Sclerosis Research

Advertisment

Multiple sclerosis (MS) is a debilitating inflammatory disease of the central nervous system, affecting an estimated 2.8 million people across the globe. It is a condition that represents a significant challenge for medical professionals, with the cause still not entirely clear. However, recent research has provided a new ray of hope, establishing a strong link between MS and the Epstein-Barr virus (EBV). Individuals infected with EBV are found to be 30 times more likely to develop MS.

Advertisment

BEHIND-MS Consortium: A Global Effort to Tackle MS

The European Union, recognizing the gravity of the situation, is funding the international 'BEHIND-MS' consortium to delve deeper into this link. The consortium includes twelve partner institutions from six European countries, all united in the mission to unravel the mysteries of MS. The funding for BEHIND-MS amounts to a generous 7.1 million euros over five years. It aims to develop new models to study the interactions of viruses, immune cells, and nerve cells, as well as identify specific biomarkers that signal different stages of the disease.

Advancing MS Research with New Models

Advertisment

One of the significant objectives of the consortium is to develop new cell and animal models to test various hypotheses on the development of MS. These models will serve as an essential tool in understanding the complex interactions between the virus, immune cells, and nerve cells, thereby providing a clearer picture of the disease's progression.

Emerging Therapies and Treatments

While the consortium is poised to make considerable strides in understanding MS, the ultimate goal remains to explore new therapeutic approaches. As part of this endeavor, the consortium will identify biomarkers that signal specific stages of the disease. This could potentially pave the way for early intervention and more effective treatment strategies.

Advertisment

Also in the realm of MS treatment, MediciNova, Inc. recently received a Notice of Decision to Grant from the European Patent Office for a pending patent application. This patent covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS), with the patent expected to remain in effect until October 2039.

Additionally, a landmark conference in Sheffield focused on the groundbreaking StarMS treatment for multiple sclerosis (MS), underscoring the effectiveness of Haematopoietic Stem Cell Transplant (HSCT) in MS. The StarMS trial evaluates the effectiveness and safety of Autologous Haematopoietic Stem Cell Transplantation (aHSCT) compared to advanced Disease Modifying Therapies (DMTs).

Conclusion

Multiple sclerosis continues to be a complex, debilitating disease affecting millions worldwide. However, the concerted efforts of the international community, led by initiatives like the BEHIND-MS consortium, offer a beacon of hope. With continued research, the development of new models, and the exploration of novel therapeutic approaches, the day when MS can be effectively managed, if not entirely eradicated, may not be too far off.

Advertisment
Chat with Dr. Medriva !